Patient Death in Phase 2b Prostate Cancer Trial Unrelated to Topsalysin, Sophiris Says

Patient Death in Phase 2b Prostate Cancer Trial Unrelated to Topsalysin, Sophiris Says
Topsalysin (PRX302), an investigative agent for localized prostate cancer, is unlikely to have caused the death of a patient in a Phase 2b trial testing the medicine, Sophiris Bio announced. A review of clinical records and information from the autopsy point to a sudden cardiac event caused by an arrhythmia as the most likely cause of death; the patient had multiple risk factors for the condition. Bloodwork also excluded an acute hypersensitivity to the drug. The patient died after a second administration of topsalysin in a Phase 2b trial (NCT03081481
Subscribe or to access all post and page content.